Many potential immune therapeutic targets are similarly affected in adult-onset
neurodegenerative diseases, such as Alzheimer's (AD) disease, Parkinson's disease (PD) …

The relative importance of antimuscarinic anticholinergic medications for Parkinson's
disease (PD) declined after the introduction of levodopa, such that anticholinergic …

Historically, pathological brain lesions provided the foundation for localization of symptoms
and therapeutic lesions were used as a treatment for brain diseases. New medications …

Introduction Non-motor symptoms (NMS) affect patients with Parkinson's disease (PD) from
the prodromal to the advanced stages. NMS phenotypes greatly vary and have a huge …

Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's disease (AD). It is characterized by a progressive loss of dopaminergic neurons …

Aims We performed cell and animal experiments to explore the therapeutic effect of
artemisinin on Parkinson's disease (PD) and the TLR4/Myd88 signaling pathway. Methods …

Background: Cognitive impairment is a staggering personal and societal burden;
accordingly, there is a strong interest in potential strategies for its prevention and treatment …

Alzheimer's disease and Parkinson's disease are the two most common neurodegenerative
diseases in the world, and their incidence rates are increasing as our society ages. This …

Cognitive decline in Parkinson's disease is related to cholinergic system degeneration,
which can be assessed in vivo using structural MRI markers of basal forebrain volume and …

Aim: To investigate whether the estimation of cerebrospinal fluid (CSF) and brain YKL-40
levels may be used as an efficient biomarker for Parkinson's disease (PD). Methods …